 Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 3 | 2 | 5 | | 2000 | 3 | 1 | 4 | | 2001 | 1 | 2 | 3 | | 2002 | 2 | 2 | 4 | | 2003 | 7 | 1 | 8 | | 2004 | 5 | 6 | 11 | | 2005 | 3 | 11 | 14 | | 2006 | 3 | 6 | 9 | | 2007 | 9 | 11 | 20 | | 2008 | 11 | 8 | 19 | | 2009 | 15 | 16 | 31 | | 2010 | 17 | 8 | 25 | | 2011 | 14 | 11 | 25 | | 2012 | 23 | 5 | 28 | | 2013 | 16 | 15 | 31 | | 2014 | 23 | 12 | 35 | | 2015 | 24 | 7 | 31 | | 2016 | 19 | 11 | 30 | | 2017 | 29 | 20 | 49 | | 2018 | 36 | 19 | 55 | | 2019 | 27 | 15 | 42 | | 2020 | 22 | 38 | 60 | | 2021 | 12 | 35 | 47 | | 2022 | 7 | 47 | 54 | | 2023 | 5 | 33 | 38 | | 2024 | 39 | 34 | 73 | | 2025 | 20 | 2 | 22 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Knowler WC, Doherty L, Edelstein SL, Bennett PH, Dabelea D, Hoskin M, Kahn SE, Kalyani RR, Kim C, Pi-Sunyer FX, Raghavan S, Shah VO, Temprosa M, Venditti EM, Nathan DM. Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial. Lancet Diabetes Endocrinol. 2025 06; 13(6):469-481.
-
Berget C, Annan SF, Biester T, Choudhary P, Forlenza GP, Peters AL, Renard E, Deiss D. Practical considerations for using the Omnipod? 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe. Diabetes Obes Metab. 2025 Jun; 27(6):2909-2919.
-
Utzschneider KM, Tripputi M, Butera NM, Mari A, Rosin SP, Banerji MA, Bergenstal RM, Brown N, Carlson AL, DeFronzo RA, Gramzinski MR, Harindhanavudhi T, Kozedub A, Sivitz WI, Steffes MW, Balasubramanyam A, Rasouli N. Differential Treatment Effects on ?-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2025 Apr 01; 48(4):623-631.
-
Witham MD, McDonald C, Wilson N, Rennie KJ, Bardgett M, Bradley P, Clegg AP, Connolly S, Hancock H, Hiu S, Nicholson K, Robertson L, Simms L, Steel AJ, Steves CJ, Storey B, Wason J, von Zglinicki T, Sayer AA. Metformin and physical performance in older people with probable sarcopenia and physical prefrailty or frailty in England?(MET-PREVENT): a double-blind, randomised, placebo-controlled trial. Lancet Healthy Longev. 2025 Mar; 6(3):100695.
-
Mason E, Karakus KE, Akturk HK. Barriers to glucagon use in patients with type 1 diabetes. Prim Care Diabetes. 2025 Jun; 19(3):341-343.
-
King J, Buschur E, Garcetti R, Pyle L, Sakamoto C, Snell-Bergeon J, Nease E, Bartholomew A, Dungan K, Polsky S. Changes to insulin pump settings throughout pregnancy for individuals using assisted hybrid closed-loop therapy versus sensor-augmented pump therapy. J Diabetes Complications. 2025 Apr; 39(4):109000.
-
Hirsch IB, Beck RW, Marak MC, Kudva Y, Akturk HK, Bhargava A, Codorniz K, Diner J, Aleppo G, Blevins T, Levy CJ, Raskin P, Castorino K, Manessis A, Pickering D, Steenkamp DW, Weinstock RS, Bode BW, Hamdy O, Nguyen QT, Kipnes M, Ruedy KJ, Desjardins D, Haider Z, Jacobson C, Lee S, Buse JB, Klein KR, O'Malley G, Church MM, Mottalib A, Baran JD, Kurek C, Rizvi S, Donahue C, Tamarez D, Atakov Castillo A, Borgman S, Frey S, Calhoun P. A Randomized Trial Comparing Inhaled Insulin Plus Basal Insulin Versus Usual Care in Adults With Type 1 Diabetes. Diabetes Care. 2025 Mar 01; 48(3):353-360.
-
T Onetto M, Montt-Blanchard D, Berget C, Strodhoff K, Grassi B. Use of an Advanced Hybrid Closed Loop System During Marathon Running: Case Examples and Clinical Implications. Diabetes Metab Res Rev. 2025 Mar; 41(3):e70034.
-
Beck RW, Bailey RJ, Akturk HK, Rizvi S, Kudva Y, Blevins T, Church MM, Manessis A, Calhoun P, Ruedy KJ, Hirsch IB. A 13-Week Single-Arm Evaluation of Inhaled Technosphere Insulin Plus Insulin Degludec for Adults with Type 1 Diabetes. Diabetes Technol Ther. 2025 Mar; 27(3):161-169.
-
Garg SK, Kaur G, Renner D, Lanning MS, Mason E, Beatson C, Ciesco K, Snell-Bergeon J. Cardiovascular and Renal Biomarkers in Overweight and Obese Adults with Type 1 Diabetes Treated with Tirzepatide for 21 Months. Diabetes Technol Ther. 2025 Mar; 27(3):152-160.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|